Aptorum Group Shares Drop After Direct Offering Prices

Dow Jones10-10

By Chris Wack

Aptorum Group shares were 24% lower, at $1.80, after the company said it has entered into definitive agreements for the purchase and sale of 1 million shares at $2 a share in a registered direct offering.

In a concurrent private placement, the biopharmaceutical company said it will also issue unregistered warrants to buy up to 2 million shares at an exercise price of $2 per share.

The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants.

The closing of the offering is expected to occur on or about Tuesday.

The proceeds to Aptorum from the offering are expected to be $2 million before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be $4 million.

The company said it intends to use the proceeds from the offering to fund expenses expected to be incurred in connection with the previously announced merger agreement between Aptorum and DiamiR Biosciences, and for general working capital for the two companies pending anticipated closing of the merger.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 10, 2025 10:18 ET (14:18 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574517262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574517262","market":"other","top_or_hot":-1,"title":"Aptorum Group Shares Drop After Direct Offering Prices","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Aptorum Group shares were 24% lower, at $1.80, after the company said it has entered into definitive agreements for the purchase and sale of 1 million shares at $2 a share in a registered direct offering. \n</p>\n<p>\n  In a concurrent private placement, the biopharmaceutical company said it will also issue unregistered warrants to buy up to 2 million shares at an exercise price of $2 per share. \n</p>\n<p>\n  The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants. \n</p>\n<p>\n  The closing of the offering is expected to occur on or about Tuesday. \n</p>\n<p>\n  The proceeds to Aptorum from the offering are expected to be $2 million before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be $4 million. \n</p>\n<p>\n  The company said it intends to use the proceeds from the offering to fund expenses expected to be incurred in connection with the previously announced merger agreement between Aptorum and DiamiR Biosciences, and for general working capital for the two companies pending anticipated closing of the merger. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 10, 2025 10:18 ET (14:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptorum Group Shares Drop After Direct Offering Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptorum Group Shares Drop After Direct Offering Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-10 22:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Aptorum Group shares were 24% lower, at $1.80, after the company said it has entered into definitive agreements for the purchase and sale of 1 million shares at $2 a share in a registered direct offering. \n</p>\n<p>\n  In a concurrent private placement, the biopharmaceutical company said it will also issue unregistered warrants to buy up to 2 million shares at an exercise price of $2 per share. \n</p>\n<p>\n  The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants. \n</p>\n<p>\n  The closing of the offering is expected to occur on or about Tuesday. \n</p>\n<p>\n  The proceeds to Aptorum from the offering are expected to be $2 million before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be $4 million. \n</p>\n<p>\n  The company said it intends to use the proceeds from the offering to fund expenses expected to be incurred in connection with the previously announced merger agreement between Aptorum and DiamiR Biosciences, and for general working capital for the two companies pending anticipated closing of the merger. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 10, 2025 10:18 ET (14:18 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APM","symbol_name":"知临集团","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2574517262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574517262","pubTimestamp":1760105880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aptorum Group shares were 24% lower, at $1.80, after the company said it has entered into definitive agreements for the purchase and sale of 1 million shares at $2 a share in a registered direct offering.In a concurrent private placement, the biopharmaceutical company said it will also issue unregistered warrants to buy up to 2 million shares at an exercise price of $2 per share.The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants.The closing of the offering is expected to occur on or about Tuesday.The proceeds to Aptorum from the offering are expected to be $2 million before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be $4 million.The company said it intends to use the proceeds from the offering to fund ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APM":"知临集团","BK4139":"生物科技"},"translate_title":"Aptorum集团股价在直接发行价后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APM":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Aptorum Group shares were 24% lower, at $1.80, after the company said it has entered into definitive agreements for the purchase and sale of 1 million shares at $2 a share in a registered direct offering. \n\n\n  In a concurrent private placement, the biopharmaceutical company said it will also issue unregistered warrants to buy up to 2 million shares at an exercise price of $2 per share. \n\n\n  The warrants will be exercisable upon issuance and will expire 24 months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants. \n\n\n  The closing of the offering is expected to occur on or about Tuesday. \n\n\n  The proceeds to Aptorum from the offering are expected to be $2 million before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be $4 million. \n\n\n  The company said it intends to use the proceeds from the offering to fund expenses expected to be incurred in connection with the previously announced merger agreement between Aptorum and DiamiR Biosciences, and for general working capital for the two companies pending anticipated closing of the merger. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 10, 2025 10:18 ET (14:18 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574517262","isCrawlerRequest":true}